There are currently 25 active clinical trials seeking participants for COVID19 research studies. The states with the highest number of trials for COVID19 participants are Florida, Texas, California and New York.
COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications
NCT04535128
Recruiting
Novel coronavirus 2019 (COVID-19) has emerged as a major international public health concern. While much of the morbidity and mortality associated with COVID-19 has been attributed to acute respiratory distress syndrome (ARDS) or end-organ failure, emerging data suggest that disorders of coagulation, in particular hypercoagulability and venous thromboembolism (VTE), may represent an additional major, and possibly preventable, complication (Wu C, et al. JAMA Intern Med. 2020 Mar 13. \[Epub ahead... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Covid19, Thrombosis Embolism, DVT, Pulmonary Embolism, Myocardial Infarction, Stroke
Register for Updates
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
NCT04956445
Recruiting
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide: 1. Acutely inf... Read More
Gender:
ALL
Ages:
Between 6 months and 120 years
Trial Updated:
12/20/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana +1 locations
Conditions: Covid19
Register for Updates
COVID-19 International Drug Pregnancy Registry
NCT05013632
Recruiting
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
COVID-19 Vaccines International Pregnancy Exposure Registry
NCT04705116
Recruiting
The objective of the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER) is to evaluate obstetric, neonatal, and infant outcomes among women vaccinated during pregnancy with a COVID-19 vaccine. Specifically, the C-VIPER will estimate the risk of obstetric outcomes (spontaneous abortion, antenatal bleeding, gestational diabetes, gestational hypertension, intrauterine growth restriction, postpartum hemorrhage, fetal distress, uterine rupture, placenta previa, chorioamnionitis, C... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/14/2023
Locations: Pregistry, Los Angeles, California
Conditions: Covid19
Register for Updates
The Nanowear Wearable Covid-19 Observational and Analysis Trend
NCT04717024
Recruiting
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a multi-site in order to collect data and analyze physiological and biometric trends due to Covid-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +1 locations
Conditions: Covid19
Register for Updates
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
NCT04896606
Recruiting
The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of \>300,000 and climbing.4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19. Virus specific cytotoxic T lymphocytes (CTLs) have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/24/2023
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Covid19
Register for Updates
Pilot Study for PET/MR Imaging of Covid-19
NCT04954248
Recruiting
The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/19/2023
Locations: Stanford University, Palo Alto, California
Conditions: Brain Diseases, Covid19
Register for Updates
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
NCT04562285
Recruiting
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Covid19
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates
iCareDx PSS-1 Point-of-Care (POC) Assay for Detection of COVID-19
NCT04937595
Recruiting
Purpose of this clinical investigation is to establish the performance of the iCareDx PSS-1 RT PCR POC Testing Platform which is used to detect COVID-19 in symptomatic patients using the patients saliva. The study focuses on obtaining a minimum of 30 positive and 30 negative test for this study. Results will serve to establish the assay's performance. Symptomatic patients who are being tested for COVID-19 will be enrolled and consented into this study. If the patient consents, 2 saliva specimens... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/22/2021
Locations: Froedtert Health WAC, Wauwatosa, Wisconsin
Conditions: Covid19
Register for Updates
Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04363502
Recruiting
In this study Investigators propose to administer clazakizumab to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/10/2021
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Covid19
Register for Updates
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
NCT04445285
Recruiting
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2021
Locations: University of South Alabama, Mobile, Alabama
Conditions: Covid19
Register for Updates